Extended Data Fig. 8: ctDNA status and association with progression-free survival by timepoint and study arm. | Nature Medicine

Extended Data Fig. 8: ctDNA status and association with progression-free survival by timepoint and study arm.

From: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Extended Data Fig. 8

(a) At C1D1, patients in Arm A with undetectable ctDNA (n = 5) had numerically longer PFS compared to patients with detectable ctDNA (n = 8), with a median PFS of 14.06 versus 2.07 months (log-rank test, p = 0.11; HR = 0.37, 95% CI: 0.1−1.32). (b) Patients in Arm B with undetectable ctDNA (n = 9) did not have significantly longer PFS compared to patients with detectable ctDNA at C1D1 (n = 4; log-rank test, p = 0.6; HR = 1.57, 95% CI: 0.29−8.55). (c) At C2D1, patients in Arm A with undetectable ctDNA (n = 6) had longer PFS compared to patients with detectable ctDNA (n = 8), with a median PFS of 22.49 versus 2.07 months (log-rank test, p = 0.00065; HR not estimable). (d) Patients in Arm B with undetectable ctDNA (n = 8) did not have longer PFS compared to patients with detectable ctDNA at C2D1 (n = 3; log-rank test, p = 0.22; HR = 3.66, 95% CI: 0.4 − 33.24). (e) At C3D1, patients in Arm A with undetectable ctDNA (n = 6) had longer PFS compared to patients with detectable ctDNA (n = 3), with a median PFS of 15.66 versus 2 months; log-rank test, p = 0.0018, HR not estimable. (f) Patients in Arm B with undetectable ctDNA (n = 8) did not have significantly longer PFS compared to patients with detectable ctDNA at C3D1 (n = 4; log-rank test, p = 0.3; HR = 0.46, 95% CI: 0.11 − 2.02). (g) At the pre-surgery timepoint, patients in Arm A with undetectable ctDNA (n = 6) had significantly longer PFS compared to patients with detectable ctDNA (n = 8), with a median PFS of 22.49 versus 2 months; log-rank test, p = 0.00029; HR not estimable. (h) Patients in Arm B with undetectable ctDNA (n = 6) did not have significantly longer PFS compared to patients with detectable ctDNA at the pre-surgery timepoint (n = 5; log-rank test, p = 0.32; HR = 0.47, 95% CI: 0.1 − 2.14). Abbreviations: ctDNA, circulating tumor DNA; PFS, progression-free survival; HR, hazard ratio; CI: confidence interval, C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1.

Back to article page